The Answer Will Come Soon
“Regeneron has some negative data with a drug that’s similar to what OPHT has,” Dennis explained.
“Traders and investors are speculating that OPHT is going to have bad data, but I don’t necessarily know that’s the case. I tend to be more positive on the name.”
Opthotech’s data is due out in December, and Dennis believes Opthotech stock will be on the move one way or another.
“It’s either going to be, in my opinion, a $15 stock or it’s going to be close to $100. It’s really important glaucoma data. If it is positive, it’s going to be transformative for this company,” he said.
He concluded the discussion by warning traders to expect extreme volatility in the stock following the release of the data. However, for traders that can stomach the risk, Opthotech is positioned for some major near-term upside.
At last check, Opthotech was trading down 9.46 percent at $30.81.
|Sep 2016||JP Morgan||Maintains||Overweight|
|Aug 2016||BTIG Research||Initiates Coverage on||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.